View : 122 Download: 0

Clinical experience of long-term use of dienogest after surgery for ovarian endometrioma

Title
Clinical experience of long-term use of dienogest after surgery for ovarian endometrioma
Authors
Chandra A.Rho A.M.Jeong K.Yu T.Jeon J.H.Park S.Y.Lee S.R.Moon H.-S.Chung H.W.
Ewha Authors
정혜원문혜성정경아이사라전지현
SCOPUS Author ID
정혜원scopus; 문혜성scopus; 정경아scopus; 이사라scopus; 전지현scopus
Issue Date
2018
Journal Title
Obstetrics and Gynecology Science
ISSN
2287-8572JCR Link
Citation
Obstetrics and Gynecology Science vol. 61, no. 1, pp. 111 - 117
Keywords
DienogestEndometriosisRecurrence
Publisher
Korean Society of Obstetrics and Gynecology
Indexed
SCOPUS; KCI scopus
Document Type
Article
Abstract
Objective Endometriosis is a common and recurring gynecologic disease which have afflicting females of reproductive age. We investigated the efficacy of long-term, post-operative use of dienogest for ovarian endometrioma. Methods We studied 203 patients who had undergone laparoscopic or robotic surgery for ovarian endometrioma, and were administrated dienogest 2 mg/day beginning in July of 2013, and continuing. We evaluated side effects of dienogest and ultrasonography was performed every 6 months to detect potential recurrence of endometrioma (2 cm) in these post-surgical patients. Results The follow-up observation periods were 30.2±20.9 months from surgery. The mean age was 34.1±7.2 years old. The mean diameter of pre-operative endometrioma was 5.6±3.0 cm2. One hundred eighty-two (89.7%) women received dienogest continuously for 12.0±7.1 months. Of the subjects, 21 (10.3%) patients discontinued dienogest at 2.4±1.0 months. The most common side effect when dienogest was discontinued was abnormal uterine bleeding. The occurrence rate of vaginal bleeding was 15.8%, a number which did not differ significantly in patients with/without post-operative gonadotropin releasing hormone agonist administration. The other side effects were gastrointestinal trouble including constipation, acne, headache, depression, hot flush, weight gain, and edema. However, no serious adverse events or side effects were documented and recurrent endometriomas were diagnosed in 3 patients (1.5%). Conclusion The data indicates that dienogest was both tolerable and safe for long-term use as prophylaxis in an effort to obviate the recurrence of ovarian endometrioma post-operatively, as well as potential need for surgical re-intervention. © 2018 Korean Society of Obstetrics and Gynecology.
DOI
10.5468/ogs.2018.61.1.111
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE